PT  - JOURNAL ARTICLE
AU  - Edlow, Andrea G.
AU  - Castro, Victor M.
AU  - Shook, Lydia L.
AU  - Haneuse, Sebastien
AU  - Kaimal, Anjali J.
AU  - Perlis, Roy H.
TI  - Sex-specific neurodevelopmental outcomes in offspring of mothers with SARS-CoV-2 in pregnancy: an electronic health records cohort
AID  - 10.1101/2022.11.18.22282448
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.18.22282448
4099  - http://medrxiv.org/content/early/2022/11/18/2022.11.18.22282448.short
4100  - http://medrxiv.org/content/early/2022/11/18/2022.11.18.22282448.full
AB  - Importance Prior studies using large registries suggested a modest increase in risk for neurodevelopmental diagnoses among children of mothers with immune activation during pregnancy, and such risk may be sex-specific.Objective To determine whether in utero exposure to the novel coronavirus SARS-CoV-2 is associated with sex-specific risk for neurodevelopmental disorders up to 18 months after birth, compared to unexposed offspring born during or prior to the pandemic period.Design Retrospective cohort.Participants Live offspring of all mothers who delivered between March 2018 and May 2021 at any of eight hospitals across two health systems in Massachusetts.Exposure PCR evidence of maternal SARS-CoV-2 infection during pregnancy.Main Outcome and Measures Electronic health record documentation of ICD-10 diagnostic codes corresponding to neurodevelopmental disorders.Results The pandemic cohort included 18,323 live births, including 877 (4.8%) to individuals with SARS-CoV-2 positivity during pregnancy. The cohort included 1806 (9.9%) Asian individuals, 1634 (8.9%) Black individuals, 1711 (9.3%) individuals of another race, and 12,694 (69%) White individuals; 2614 (14%) were of Hispanic ethnicity. Mean maternal age was 33.0 years (IQR 30.0-36.0). In adjusted regression models accounting for race, ethnicity, insurance status, hospital type (academic center vs. community), maternal age, and preterm status, SARS-CoV-2 positivity was associated with statistically significant elevation in risk for neurodevelopmental diagnoses among male offspring (adjusted OR 1.99, 95% CI 1.19-3.34; p=0.009) but not female offspring (adjusted OR 0.90, 95% CI 0.43-1.88; p=0.8). Similar effects were identified using matched analyses in lieu of regression.Conclusion and Relevance SARS-CoV-2 exposure in utero was associated with greater magnitude of risk for neurodevelopmental diagnoses among male offspring in the 12 months following birth. As with prior studies of maternal infection, substantially larger cohorts and longer follow-up will be required to reliably estimate or refute risk.Trial Registration NAQuestion Are rates of neurodevelopmental disorder diagnoses greater among male or female children with COVID-19 exposure in utero compared to those with no such exposure?Findings In a cohort of 18,323 infants delivered after February 2020, males but not females born to mothers with a positive SARS-CoV-2 PCR test during pregnancy were more likely to receive a neurodevelopmental diagnosis in the first 12 months after delivery, even after accounting for preterm delivery.Meaning These findings suggest that male offspring exposed to COVID-19 in utero may be at increased risk for neurodevelopmental disorders.Competing Interest StatementDr. Perlis has received consulting fees from Burrage Capital, Genomind, Belle Artificial Intelligence, and Takeda. He holds equity in Psy Therapeutics, Belle Artificial Intelligence, and Circular Genomics. Dr. Edlow has received consulting fees from Mirvie, Inc. and research funding from Merck Pharmaceuticals, both outside of the work reported here. The other authors report no disclosures.Funding StatementThis study was supported by the National Institute of Mental Health (RF1MH132336, Dr. Edlow and Dr. Perlis; R01 MH116270, Dr. Perlis; U54 MH118919, Dr. Edlow), the National Institute of Child Health and Human Development (R01 HD100022-02S2, Dr. Edlow), and Simons Foundation SFARI grant 870754 (Dr. Edlow).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Massachusetts General Brigham Institutional Review Board approved all aspects of this study, with a waiver of informed consent as no patient contact was required, the study was considered to be minimal risk, and consent could not feasibly be obtained.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not available because of restrictions on use of electronic health records.